FDA Approves Semaglutide for New Indication Involving Cardiovascular Disease
Pharmacy Times
MARCH 8, 2024
Semaglutide (Wegovy; Novo Nordisk) reduces the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight when combined with the standard-of-care.
Let's personalize your content